Search company, investor...
Symphogen company logo

Symphogen

symphogen.com

Stage

Acquired | Acquired

Total Raised

$364.16M

About Symphogen

Symphogen is developing next-generation antibody therapeutics for the treatment of cancer and is dedicated to bringing truly innovative oncology products to the market. The company has advanced the frontier of antibody discovery by creating well-characterized antibody mixtures that address multiple oncology targets in a single drug product. The company has matured its pipeline, currently has two product candidates in the clinic, and is researching promising novel immuno-oncology opportunities. On April 3, 2020, Symphogen was acquired by Servier. Terms of the transaction were not disclosed.

Headquarters Location

Pederstrupvej 93

Ballerup, DK-2750,

Denmark

+45 4526 5050

Missing: Symphogen's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Symphogen's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Symphogen

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Symphogen is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

838 items

Symphogen Patents

Symphogen has filed 32 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/11/2017

7/19/2022

Clusters of differentiation, Immune system, Immunology, Transcription factors, Monoclonal antibodies

Grant

Application Date

4/11/2017

Grant Date

7/19/2022

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Transcription factors, Monoclonal antibodies

Status

Grant

Latest Symphogen News

CTTQ Acquires Global Rights to Clinical Stage Symphogen Immunotherapy

May 23, 2022

publication date: May 23, 2022 Chia Tai‑Tianqing Pharma (CTTQ), a Nanjing subsidiary of Sino Biopharma, will acquire global rights to an anti-LAG3 mAb from Symphogen A/S of Denmark. Sym022 is a mAb that binds LAG3 to block the interaction with MHCII, which increases T cell proliferation and production of cytokines. In two Phase I trials, Sym022 proved itself to be safe and well-tolerated as a monotherapy and in combination with checkpoint inhibitors. Financial details of the transaction were not disclosed. Symphogen is the Antibody Center of Excellence for Servier, a privately held French biopharma. More details.... Share this with colleagues:

Symphogen Frequently Asked Questions (FAQ)

  • Where is Symphogen's headquarters?

    Symphogen's headquarters is located at Pederstrupvej 93, Ballerup.

  • What is Symphogen's latest funding round?

    Symphogen's latest funding round is Acquired.

  • How much did Symphogen raise?

    Symphogen raised a total of $364.16M.

  • Who are the investors of Symphogen?

    Investors of Symphogen include Servier, Genentech, Novo Holdings, PKA, Danica Pension and 10 more.

  • Who are Symphogen's competitors?

    Competitors of Symphogen include Humanetics, ImmunoReagents, Altor BioScience, Merus, Theraclone Sciences and 16 more.

Compare Symphogen to Competitors

PharmAthene Logo
PharmAthene

PharmAthene's primary objective is the development of effective countermeasures to a range of biological and chemical threats having potential lethal effects for the military or civilian populations. The Company is developing Valortim, an anthrax monoclonal antibody, in collaboration with Medarex, Inc. for pre- and post exposure prophylaxis and treatment, as well as Protexia, a recombinant human butyrylcholinesterase for treatment following exposure to chemical nerve agents.

Y
Y's Therapeutics

Y's Therapeutics focuses on developing monoclonal antibody therapies and other molecular-targeted biological drugs for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs. The company also have small molecule compounds in the company's R&D pipeline to diversify the company's portfolio.

A
ApoLife

ApoLife has developed platform yeast expression technologies for accelerated development of therapeutic antibodies (glycosylated and aglycosylated), antibody fragments, fusion proteins and antibodies and subunit vaccines through its Twin Cassette yeast system. ApoLife employs Bakers yeast (S.cerevisiae) which has been used for manufacturing several FDA approved therapeutic products thus giving ApoLife a competitive regulatory advantage over companies using other yeast systems. ApoLife's platform has the capability to make fully functional secreted antibodies and has potential to improve antibody potency. The technology has the capability to accelerate the process of identifying and selecting antibodies for target antigens, reducing the cost and development time by up to 50% of the current process.ApoLife uses its technology to develop anticancer antibodies and immunotoxins with collaborating partners.As a licensing partner, ApoLife has vectors, yeast strains, and production process available for antibody and biogeneric product development.

G
GRAPP

Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute (www.vai.org) and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

ImmunoReagents Logo
ImmunoReagents

ImmunoReagents is a cGMP manufacturing facility for antibodies used in the In Vitro Diagnostic Industry, which specializes in polyclonal antibodies to human proteins and secondary antibodies.

H
Humanetics

Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.